Completed PHASE3 INTERVENTIONAL NCT00211991

Evaluation of Consistency of StaphVAX Manufacturing Lots

A Phase 3, Multicenter, Double-Blinded, Randomized, Study to Compare Immunogenicity and Safety Between Three Commercial Lots of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Normal, Healthy, Adult Volunteers

Sponsor: Nabi Biopharmaceuticals

Conditions Staphylococcal Infections

Interventions S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate

Updated 6 times since 2017 Last updated: May 10, 2012 Started: Apr 30, 2005 Primary completion: Jul 31, 2005 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00211991, this PHASE3 trial focuses on Staphylococcal Infections and remains completed. Sponsored by Nabi Biopharmaceuticals, it has been updated 6 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nabi Biopharmaceuticals
Vanderbilt University

Data source: Nabi Biopharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nashville, United States